A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Surface Antigen, Inactivated, Egg-Derived, Trivalent Influenza (Agrippal) Virus Vaccine, Southern Hemisphere Formulation 2015, in Healthy Adults

Trial Profile

A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Surface Antigen, Inactivated, Egg-Derived, Trivalent Influenza (Agrippal) Virus Vaccine, Southern Hemisphere Formulation 2015, in Healthy Adults

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2015

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 08 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2015 Planned End Date changed from 1 May 2015 to 1 Jun 2015, as per ClinicalTrials.gov record.
    • 12 May 2015 Planned primary completion date changed from 1 May 2015 to 1 Jun 2015, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top